CHICAGO, Aug. 1 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. , today announced that it will host a conference call and live webcast at 10:00 a.m. Eastern Time on Thursday, August 9, 2007 to discuss the Company's second quarter financial results. Michael T. Flavin, Ph.D., Chairman & Chief Executive Officer, and other members of the management team will also present an update on the Company. A press release reporting the second quarter financial results will be issued after the U.S. stock markets close on Wednesday, August 8, 2007.
The conference call will be webcast simultaneously over the Internet. Please visit the Investor Relations section of Advanced Life Sciences' corporate website www.advancedlifesciences.com. Alternatively, callers may participate in the conference call by dialing 888-873-4896 (domestic) or 617- 213-8850 (international). The passcode for the conference call is 16007877. A telephone replay of the call will also be available for 48 hours. Callers may access the telephone replay by dialing (domestic) 888-286-8010 or 617-801- 6888 (international), passcode 88970844.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at www.advancedlifesciences.com.
Forward-Looking Statements
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward- looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, clinical trials, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.
Advanced Life Sciences Holdings, Inc.CONTACT: Joe Camp of Advanced Life Sciences Holdings, +1-630-754-4352;Media, Melanie Nimrodi, +1-312-546-3508, or Investors, Kathy Price,+1-213-486-6547, both of Financial Relations Board
Web site: http://www.advancedlifesciences.com//
